Cipla Q4 net profit down 3 percent on higher costs
MUMBAI (Reuters) - Drugmaker Cipla Ltd (CIPL.NS) on Thursday reported a 3 percent drop in fourth-quarter net profit, slightly below analysts' estimates due to higher raw material and employee expenses.
The company, among the world's largest suppliers of HIV/AIDS medicines, said January-March net profit was 2.61 billion rupees ($44.33 million), compared with 2.68 billion rupees a year earlier. Analysts on average expected 2.76 billion rupees, according to Thomson Reuters data.
Net sales rose about 15 percent to 21.94 billion rupees, while total expenses shot up 35 percent.
Cipla, one of the largest pharmaceutical companies in India, gets more than half its revenue through exports to nearly 180 overseas markets, including Africa, Latin America and the United States.
Shares of the company, down 6.4 percent so far this year, closed down 2 percent on Thursday, in line with the Nifty.($1 = 58.8750 rupees)
(Reporting by Zeba Siddiqui in Mumbai; Editing by Subhranshu Sahu)
- Tweet this
- Share this
- Digg this
- In India, rice replaces ice in bucket challenge
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- UPDATE 3-Negative euro overnight rates show cracks in banking system
- India's growth speeds up in after-glow of Modi's triumph
- Indian power station coal stocks lowest since 2012 blackouts
India's economy grew by a faster-than-expected 5.7 percent in the three months through June, its fastest pace in two-and-a- half years, helped by a rebound in manufacturing and mining sectors, government data showed on Friday. Full Article
In race for bigger margins, drug makers willing to lose the India "advantage". Full Article